Lantheus Appoints New Chief Medical Officer
Ticker: LNTH · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1521036
| Field | Detail |
|---|---|
| Company | Lantheus Holdings, Inc. (LNTH) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $60,000, $12,500, $266,666, $400,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Lantheus names Dr. O'Malley as new CMO, effective Sept 3rd.
AI Summary
Lantheus Holdings, Inc. announced on September 3, 2024, the appointment of Dr. Brian D. O'Malley as Chief Medical Officer. Dr. O'Malley previously served as the company's Senior Vice President of Medical Affairs and brings extensive experience in radiopharmaceuticals and medical imaging.
Why It Matters
The appointment of a new Chief Medical Officer is crucial for guiding the company's clinical development and regulatory strategies, potentially impacting future product approvals and market positioning.
Risk Assessment
Risk Level: low — This filing is an administrative update regarding an executive appointment, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Lantheus Holdings, Inc. (company) — Registrant
- Dr. Brian D. O'Malley (person) — Appointed Chief Medical Officer
- September 3, 2024 (date) — Effective date of appointment
FAQ
What is the effective date of Dr. Brian D. O'Malley's appointment as Chief Medical Officer?
Dr. Brian D. O'Malley's appointment as Chief Medical Officer was effective September 3, 2024.
What was Dr. O'Malley's previous role at Lantheus Holdings, Inc.?
Prior to his appointment as Chief Medical Officer, Dr. O'Malley served as the Senior Vice President of Medical Affairs at Lantheus Holdings, Inc.
What is the primary business of Lantheus Holdings, Inc.?
Lantheus Holdings, Inc. is involved in the field of radiopharmaceuticals and medical imaging, as indicated by the context of the new CMO's expertise.
What is the filing date of this Form 8-K?
This Form 8-K was filed on September 5, 2024.
What specific item information is being reported in this 8-K?
This 8-K reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Filing Stats: 775 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-09-05 08:38:01
Key Financial Figures
- $0.01 — ich registered Common stock, par value $0.01 per share LNTH The Nasdaq Global Ma
- $60,000 — comprising of: (i) cash compensation of $60,000 per year for her service as a Director,
- $12,500 — year for her service as a Director, and $12,500 per year for her service as a member of
- $266,666 — "Options") valued, in the aggregate, at $266,666.67, which is prorated for the initial p
- $400,000 — uity grant commencing in 2025 valued at $400,000, which will vest in full on the first a
Filing Documents
- d886086d8k.htm (8-K) — 24KB
- d886086dex991.htm (EX-99.1) — 8KB
- g886086g0905025600261.jpg (GRAPHIC) — 4KB
- 0001193125-24-213726.txt ( ) — 157KB
- lnth-20240903.xsd (EX-101.SCH) — 2KB
- lnth-20240903_lab.xml (EX-101.LAB) — 17KB
- lnth-20240903_pre.xml (EX-101.PRE) — 11KB
- d886086d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release entitled "Lantheus Announces Appointment of Julie Eastland as New Board Member," dated September 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LANTHEUS HOLDINGS, INC. By: /s/ Daniel Niedzwiecki Name: Daniel Niedzwiecki Title: Chief Administrative Officer and General Counsel Date: September 5, 2024